Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

Cancer

Volumn 97, Issue 12, 2003, Pages 2972-2977

  Bendell, Johanna C ^a   Domchek, Susan M ^b   Burstein, Harold J ^a   Harris, Lyndsay ^a   Younger, Jerry ^c   Kuter, Irene ^c   Bunnell, Craig ^a   Rue, Montse ^a   Gelman, Rebecca ^a   Winer, Eric ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Central nervous system (CNS) metastases; HER 2 neu; Metastatic breast carcinoma; Trastuzumab

Indexed keywords

TRASTUZUMAB;

ADULT; ALGORITHM; ARTICLE; BLOOD BRAIN BARRIER; BREAST CARCINOMA; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG PENETRATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MENINGEAL NEOPLASMS; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0038010542     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11436     Document Type: Article

References (24)

1. Benz CC, O'Hagan RC, Richter B, et al. HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene. 1997;15:1513-1525.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177-182.
3. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p 185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14:737-744.
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17: 2639-2648.
5. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.
6. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 1999;18:127a.
7. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelobine in women with HER-2 overexpressing metastatic breast cancer. J Clin Oncol. 2001;19: 10:2722-2730.
8. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20: 1800-1808.
9. Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol. 2001;20(1 Suppl 3):28-37.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 from metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;11:783-792.
11. Takakura K, Sano K, Hojo S, et al. Metastatic tumors of the central nervous system. Tokyo: Igaku-Shoin, 1982.
12. DiStefano A, Yap HY, Hortobagyi GN, et al. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44:1913-1918.
13. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastases from breast carcinoma: autopsy study. Cancer. 1983;52:2349-2354.
14. Lee Y. Breast carcinoma: pattern of metastatic spread at autopsy. J Surg Oncol. 1983;23:175-180.
15. Barron KD, Hirano A, Araki S, et al. Experiences with metastatic neoplasms involving the spinal cord. Neurology. 1959;9:91-95.
16. Sondak V. Leptomeningeal spread of breast cancer: report of case and review of the literature. Cancer. 1981;48:395-399.
17. Pestalozzi BC, Brignoli S, Trastuzumab in CSF. J Clin Oncol. 2000;11:2349-2351.
18. Lai RK, Dang C, Thaler H, et al. The incidence of brain metastases in HER2/neu+ stage IV breast cancer patients [abstract]. Proc Am Soc Clin Oncol. 2001;666a.
19. Miller KD, Weathers T, Haney LG. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors, and impact on overall survival [abstract]. Breast Cancer Res Treat. 2001;69:240a.
20. Wardley AM, Danson S, Clayton AJ, et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center [abstract]. Proc Am Soc Clin Oncol. 2002;241.
21. Eitzen R, Zach L, Kaufman B, et al. High incidence of brain metastases (BM) in patients on trastuzumab (H) for advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002;31b.
22. Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res and Treat. 2000;62:211.
23. Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol. 2000;21: 1064.
24. Esteva FJ, Sahin AA, Cristofanilli M, et al. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002;12:319-328.